HR+ Breast Cancer: 2022 Year in Review : Episode 3
New Data and Clinical Factors Contributing to CDK4/6 Inhibitor Selection
Two breast cancer experts delve into key data from various CDK4/6 inhibitor studies, focusing on safety, efficacy, and how these agents might be implemented in the clinic.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
